Abstract 17138: Emergence of a Unique Biomarker Signature in Pediatric Patients With Developing Chemotherapy Cardiotoxicity

Background: A class of chemotherapeutics commonly used in pediatric cancer is the anthrycylines (ACs), but often is associated with left ventricular dysfunction: i.e. chemotherapy induced cardiotoxicity (CIC). The goal of this project was to examine whether a specific set of plasma biomarkers could be identified in pediatric patients undergoing initial AC treatment and at risk for CIC as well as examined in relationship to referent normal pediatric patients. Methods and Results: AC treated pediatric patients (n=17, diagnosed with cancer (most commonly Hodgkin’s Lymphoma) with set dosing intervals and maximal AC doses of 325 mg/m2)) underwent cardiac MRI 24-48 hours after AC therapy for LV ejection fraction (LVEF) and plasma obtained at baseline (initial AC treatment) and with repeat studies (up to 12 mos). Plasma was also collected from referent normal pediatric subjects (n=66). Multiplex arrays quantified signatures from the inflammatory (8 unique cytokines) and matrix remodeling (13 unique matrix metall...